 |
|
|
Five analysts and top management from fifty two sector firms examine the Healthcare sector in this 197 - page CIBC World Markets Thirteenth Annual Healthcare Conference Issue from The Wall Street Transcript. |
|
- Specialty Pharmaceuticals - In an in-depth (5,500 words) Analyst interview, Dr. Steven Gerber, a Senior Pharmaceutical Industry Analyst & Head of Healthcare Research for CIBC World Markets, examines the outlook for the sector and shares specific stock recommendations.
- Medical Devices - In an in-depth (3,400 words) Analyst interview, John Calcagnini, an analyst at CIBC World Markets, examines the outlook for the sector and shares specific stock recommendations.
- Large Cap Pharmaceuticals - In an in-depth (2,000 words) Analyst interview, Mara Goldstein, an Executive Director in Equity Research with CIBC World Markets, examines the outlook for the sector and shares specific stock recommendations.
- Healthcare Facilities - In an in-depth (4,100 words) Analyst interview, Charles Lynch, an analyst at CIBC World Markets, examines the outlook for the sector and shares specific stock recommendations.
- Health Insurance & Clinical Lab Providers - In an in-depth (3,000 words) Analyst interview, John Szabo, an analyst at CIBC World Markets, examines the outlook for the sector and shares specific stock recommendations.
- CEO interviews (average 2,500 words). Top management of fifty two - sector firms examine the outlook for their firm and the sector. Firms include:
AaiPharma Inc., Advanced Neuromodulation Systems, ARIS Medical, Inc., AmeriPath, Inc., AMN Healthcare Services, Inc., AmSurg Corp., Angiotech Pharmaceuticals, Inc., AnorMED Inc., Applied Molecular Evolution, Inc., Atrix Laboratories, Inc., Bard (C.R.) Inc., Biogen, Inc., BioMarin Pharmaceutical Inc., Caliper Technologies Corp., Cambridge Antibody Technology Group, Cardiac Science, Inc., Centene Corporation, Corgentech Inc., Corvas international, Inc., Cross Country, Inc., Cygnus, Inc., Dyax Corporation, EmergingMed.com, Inc., EXACT Sciences Corporation, Exelixis, Inc., First Health Group Corp., GlaxoSmithKline Plc, Health Management Associates, Inc., Immunomedics, Inc., Integra LifeSciences Holdings Corp., Interpore Cross International, Invitrogen Corporation, Kindred Healthcare, Inc., Kosan Biosciences Inc., MDS Proteomics, Inc., Medicines Company, MGI PHARMA, Inc., MIM Corporation, Myogen, Inc., Myriad Genetics, Inc., Neurocrine Biosciences, Inc., PacifiCare Health Systems, Inc., Paladin Labs Inc., Seattle Genetics, Inc., Select Medical Corp., SICOR Inc., Signature BioScience, Inc., Stressgen Biotechnologies Corp., TLC Vision Corp., Urologix, Inc., VCA Antech, Inc., ViroLogic, Inc., XOMA Ltd.
This Issue costs $175 - and is non-returnable.
The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.
|
|
Investors and Industry Execs.
The Wall Street Transcript has been read and used by investors and industry executives for nearly 40 years. It's a vital and unique tool for doing company and industry research - as part of a stock purchase decision or as part of a market analysis.
Investors:
TWST's roundtable panels and analyst interviews provide a sector perspective from Wall Street's best. Find out where they agree, and where they disagree on stock recommendations. Money manager interviews provide the view from the buy-side. And CEO interviews with hundreds of companies from the major sectors gives the company perspective right from the top.
Industry Executives:
Get the insider view on the sector from Wall Street Analysts and Company CEO's. Company strategies, growth ambitions, new products and markets, management - these and much more are discussed by the top executives in the industry. TWST's reports should be a key part of any industry research.
Subscribe to a unique research tool for investors and industry executives. Call (212) 952 7433 or click here.
Sincerely,
Andrew Pickup
Publisher
|
|
|
